Lifeboat Foundation

“People on metformin have 30% lower rates of almost every kind of cancer. It delays cognitive decline. Even people with diabetes who are obese and have more disease to start with but are on metformin have lower mortality rates than people without diabetes who aren’t on the drug.”

What he says is born out in numerous studies. Overall, this safe, super-cheap, decades-old drug not only treats diabetes, but it also seems to delay and compress the years of chronic illness associated with the final stage of life and extend what geroscientists call the “healthspan.”

Metformin is just one of many medications, including other old ones and some brand new inventions, that academic researchers and biotech startups are exploring to slow, stop, or perhaps even reverse aging.

While the mental has often played second fiddle to the physical when it comes to longevity research, this is changing – and not a moment too soon.

The physical and mental aspects of aging are interconnected, and given the strong connection between psychology and the physical pace of aging, poor mental health is starting to be recognised as a major driver of aging.

A raft of developments have demonstrated that physical lifespan and healthspan can be extended and improved, and now it is time for the longevity industry to achieve similar success when it comes to mental health. Sergey Jakimov, the CEO of Swiss investment group LongeVC agrees, and tells us why it’s time for VCs to get excited about backing startups delivering cutting-edge solutions for mental healthcare.

At just 40 years old, Kristen Fortney has spent more than half of her life thinking about the science of aging. But why?

“When I get asked this question I usually blame it on reading too much science fiction,” the CEO and co-founder of the clinical-stage biotech BioAge Labs said with a laugh. “My co-founder, Eric Morgen, and I have been talking about aging since high school.”

George Church is a geneticist known for his pioneering work in developing new technologies for genome sequencing, editing, and synthesis. He has also been involved in research on genome engineering and gene therapy.

Links.
https://wyss.harvard.edu/team/core-faculty/george-church/
https://arep.med.harvard.edu/

Continue reading “George Church: Biomanufacturing, CRISPR,1 million cell edits, Woolly mammoth-Learning with Lowell-164” »

Call it naive, call it crazy, but I think we have a real chance to tackle aging in this century. And though it’s not easy — it’s very simple.

If you have seen the banner of this channel — it says it’s all. But in this video I go deeper into my personal story and motivation. This way I hope you can understand why I’m doing what I’m doing.

Continue reading “I Want You To Live to 150… Here’s Why & How” »

So much here I never knew:

Dr. Axel Montagne is a chancellor’s fellow and group leader at the UK Dementia Research Institute at the University of Edinburgh Centre for Clinical Brain Sciences. His group aims to understand how, when, and where critical components of the blood-brain barrier become dysfunctional preceding dementia and in the earliest stages of age-related cognitive decline. With this knowledge, they hope to develop precise treatments targeting brain vasculature to protect brain function.

Continue reading “Axel Montagne, PhD, on Solving Alzheimer’s and Dementia with Blood-Brain Barrier Repair” »

In recent decades, extracellular vesicles have been recognized as “very important particles” (VIPs) associated with aging and age-related disease. During the 1980s, researchers discovered that these vesicle particles released by cells were not debris but signaling molecules carrying cargoes that play key roles in physiological processes and physiopathological modulation. Following the International Society for Extracellular Vesicles (ISEV) recommendation, different vesicle particles (e.g., exosomes, microvesicles, oncosomes) have been named globally extracellular vesicles. These vesicles are essential to maintain body homeostasis owing to their essential and evolutionarily conserved role in cellular communication and interaction with different tissues. Furthermore, recent studies have shown the role of extracellular vesicles in aging and age-associated diseases.

We’ve known about telomeres for more than 80 years, but these tiny, protective structures at the end of the chromosomes keep revealing secrets to us, including the possibility of having surprising functions.

It turns out that these key biological cogs can produce proteins, something previously thought impossible due to their simplicity.

While it’s not clear yet what these proteins might do, the fact that they exist at all is significant.

Aging is a complex process, a river fed by several tributaries connected by countless interweaving streams. Its direction is set inexorably towards infirmity, or so it would first appear. Daunting as navigation may seem, their interrelatedness should inspire hope instead of fear.

Aging is undeniably the root of the most common and costly noncommunicable diseases in the developed world, as well as a predisposing factor to severe or fatal reactions to infectious ones. Whatever can be done to slow, halt, or reverse its course holds inestimable economic and humanitarian value (Lee, 2017).

The hallmarks of aging were assembled to broadly conceptualize what lies behind phenomena as seemingly unrelated as gray hair, wrinkles, heart disease, cognitive decline, and cancer. They serve as explanations for why everything from our joints to our eyesight steadily give out over time.